Phreesia saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 89 to 92.
This proprietary rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the best stocks typically have an RS Rating of over 80 as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Phreesia is now considered extended and out of buy range after clearing a 26.45 buy point in a first-stage double bottom. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Phreesia posted 0% EPS growth in the latest quarterly report, while sales growth came in at 17%.
Phreesia holds the No. 7 rank among its peers in the Computer Software-Medical industry group. Doximity, Waystar Holding and Veeva Systems Cl A are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
